SMAD3 and medulloblastoma: Determining to what extent high AHRR expression in human SHH medulloblastoma is associated with elevated TGFβ-SMAD3 signalling will be an important next step to identify patients that may benefit from TGFβ-SMAD3 inhibition and/or AHR agonist therapies.